Dendritic cell vaccine - Argos Therapeutics/Pharmstandard

Drug Profile

Dendritic cell vaccine - Argos Therapeutics/Pharmstandard

Alternative Names: AGS003-like therapy

Latest Information Update: 30 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Argos Therapeutics Inc
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Renal cell carcinoma

Most Recent Events

  • 18 Nov 2016 Preclinical trials in Renal cell carcinoma in USA and Russia (unspecified route)
  • 01 Aug 2013 Argos signed an license agreement with Pharmastandard for the development, manufacturing and commercialisation of AGS 003 and other products in Russia, Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Ukraine and Uzbekistan (Argos Therapeutics' Form 10-K, December 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top